{"id":2860,"date":"2018-08-08T18:10:34","date_gmt":"2018-08-08T12:40:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2860"},"modified":"2021-07-24T12:57:01","modified_gmt":"2021-07-24T07:27:01","slug":"snippet-migraine","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine","title":{"rendered":"Snippet : Migraine"},"content":{"rendered":"

Teva\u2019s migraine drug is expected to launch this year despite the delay in FDA approval<\/strong><\/p>\n

Teva Pharmaceutical\u2019s fremanezumab for treating migraine <\/a>is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a Form 483\u00a0for its plant in Incheon, South Korea on tuesdsy. Eight manufacturing violations were observed by the drug regulators. Since January, Celltrion has been critical of the Incheon plant, when it sent a warning letter detailing how \u2014 among other things \u2014 there weren’t written procedures in place to prevent microbial contamination of drug products. In May Amgen and Novartis’ Aimovig (erenumab) received FDA approval for that indication. Fremanezumab will be second in the market and it seems that there is a three-month delay on FDA\u2019s approval for fremanezumab.<\/p>\n","protected":false},"excerpt":{"rendered":"

Teva\u2019s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a Form 483\u00a0for its plant in Incheon, South Korea on tuesdsy. Eight manufacturing violations were observed by the drug regulators. Since […]<\/p>\n","protected":false},"author":1,"featured_media":2874,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[17644,423,562],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-2860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-migraine-amgen","tag-novartis","tag-teva","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nSnippet : Migraine - DelveInsight Business Research LLP....<\/title>\n<meta name=\"description\" content=\"Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-migraine\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet : Migraine - DelveInsight Business Research LLP....\" \/>\n<meta property=\"og:description\" content=\"Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-migraine\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-08T12:40:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"416\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet : Migraine - DelveInsight Business Research LLP....","description":"Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine","og_locale":"en_US","og_type":"article","og_title":"Snippet : Migraine - DelveInsight Business Research LLP....","og_description":"Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-08T12:40:34+00:00","article_modified_time":"2021-07-24T07:27:01+00:00","og_image":[{"width":416,"height":416,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine","url":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine","name":"Snippet : Migraine - DelveInsight Business Research LLP....","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416.jpg","datePublished":"2018-08-08T12:40:34+00:00","dateModified":"2021-07-24T07:27:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Teva Pharmaceutical\u2019s fremanezumab for treating migraine is expected to launch later this year. \u00a0Celltrion disclosed that U.S. drug regulators issued\u00a0a","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-migraine"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-migraine#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416.jpg","width":416,"height":416,"caption":"migraine"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09172140\/teva-pharmaceutical_416x416-300x300.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Migraine Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Teva<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Migraine Amgen<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Teva<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 8, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 8, 2018 6:10 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2860"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2860\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2874"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2860"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2860"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}